Market Overview

Benzinga's Top Pre-Market Gainers

Related LXRX
Biotech Stock Roundup: MannKind PDUFA Date Pushed Out, Alkermes Impresses with Data - Analyst Blog
Encouraging Results from Lexicon Candidate - Analyst Blog
Related TEVA
Teva Settles Patent Litigation with Pfizer on Celebrex; Has Received Tenative FDA Approval for All Strengths; May Start Generic Versions in December
Market Wrap For April 16: Markets Hold On To Gains On Positive Yellen Comments And Economic Data
Pfizer Loses Bid to Hold Celebrex Exclusivity to '15 (Fox Business)

Lexicon Pharmaceuticals (NASDAQ: LXRX) surged 21.99% to $2.33 in the pre-market session. Lexicon Pharmaceuticals reported positive results of LX4211 Phase 2b trial for type 2 diabetes.

Teva Pharmaceutical Industries Limited (NASDAQ: TEVA) added 6.87% to $40.62 in the pre-market session. Teva reported favorable court ruling in COPAXONE® patent infringement litigation.

Watson Pharmaceuticals (NYSE: WPI) moved up 2.37% to $72.70 in the pre-market session. Watson Pharmaceuticals entered into a new senior secured term loan facility in an aggregate principal amount of $1.8 billion..

SanDisk (NASDAQ: SNDK) soared 1.35% to $36.85 in the pre-market trading. Analysts at Goldman Sachs upgraded SanDisk from “neutral” to “buy.”

Posted-In: Top Pre-Market GainersNews Pre-Market Outlook Markets Movers

 

Most Popular

Related Articles (LXRX + SNDK)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free